NasdaqGS:ARWRBiotechs
Arrowhead (ARWR): Do Strong Q1 Results and Plozasiran Hopes Outweigh Insider Selling Signals?
Arrowhead Pharmaceuticals recently delivered strong first quarter fiscal 2026 results that exceeded earnings and revenue expectations, while its Chief Medical Officer James C. Hamilton sold 10,000 shares on March 5, 2026 under a 10b5-1 trading plan, retaining direct ownership of 236,958 shares.
Alongside the better-than-expected quarter, investors are closely watching Arrowhead’s Phase 3 plozasiran SHASTA3/4 trial, which analysts have identified as an important upcoming potential catalyst...